Unlike newly diagnosed patients with Ph+ CML-CP—in whom the majority had a biphasic response—approximately half of patients with imatinib-resistant or -intolerant CML had a slower, monophasic response. Here, CP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.